Enteric diseases in poultry result in a number of problems including food safety, performance losses, and increased mortality. Necrotic enteritis is one of the most common enteric diseases in poultry and the worldwide annual loss is estimated to be over $2 billion. Therefore, Elanco desires novel approaches for the prevention, treatment, or control of necrotic enteritis in poultry.
*** Webinar *** An online webinar presented by Elanco and InnoCentive concerning Elanco's Grand Challenge Program will be held on October 20, 2016 at 10:30 AM (US Eastern Time). The webinar will include a question and answer session. Register in advance here: https://innocentive.webex.com/innocentive/j.php?RGID=re71ea91971dce8a5bd40cbb6d0d0b74c.
After registering, you will receive a confirmation email with a link to join the webinar. A recording will be attached to this Challenge for those who are unable to attend.
This Theoretical Challenge requires only a written proposal.
Necrotic enteritis is caused by Clostridium perfringens, a Gram-positive bacterium commonly found in the environment and in the gut of both humans and animals. Antibiotics through feed and water adequately control the disease, but regulations are in place to remove these growth-promoting and shared-class antibiotics from poultry production. In order to maintain intestinal tract health, there is a need for alternative options to control the disease and keep the animals healthy. Therefore, Elanco desires novel approaches for the prevention, treatment, or control of necrotic enteritis in poultry.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on November 28, 2016.
Late submissions will not be considered.
ABOUT THE SEEKER
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for nearly 7,000 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Elanco has committed to an 8-step Antibiotic Stewardship Plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use, and replaces antibiotics with alternatives. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.
What is a Theoretical IP Transfer Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.